

# Mike Eaton

has worked in the pharmaceutical industry for over 35 years, unusually working on both NCEs and NBEs. After a Ph.D. training as a nucleic acid chemist at Warwick University he worked at G D Searle for 7 years as a senior research investigator in DNA synthesis. He was a founding member of Celltech in 1980 where as Head of Chemistry he set up the Chemistry group and built the first European DNA synthesiser, which is now in the Science Museum in London. Working with Lederle, now Wyeth, he was part of the international team to research Mylotarg, the first antibody drug conjugate to get to the market. He is currently chair of the drug delivery working group and Executive board member of the ETP on nanomedicines. Mike is a Special Professor at Nottingham University and an Editorial Board member of Nanomedicine and Future Medicinal Chemistry.

